title: Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and tolerability of docetaxel and cisplatin plus S-1 (DCS) combination chemotherapy in advanced gastric cancer patients.
  
  
  METHODS
  Chemo-naive patients with advanced gastric cancer, ECOG performance status of 0 to 1, and adequate organ function were eligible. All patients received docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) on day 1, plus S-1 orally 40-60 mg bid depending on body surface area on days 1-14, every 21 days. Efficacy and adverse events were evaluated every two cycles.
  
  
  RESULTS
  Fifty-nine patients were enrolled from February 2009 to January 2011 and 56 of them were evaluated for efficacy and tolerability. After a median follow up of 17.6 months, the objective response rate (RR) was 75%, the disease control rate (DCR) 83.9%, the median progression free survival (PFS) and overall survival (OS) 6.5 (95% CI, 5.6-7.3) months and 15.5 (95% CI, 13.9-17.0) months, respectively. The median number of chemotherapy cycles was 5. Grade 3 or 4 adverse effects included neutropenia (60.7%), vomiting (14.3%), neurotoxicity (12.5%), thrombocytopenia (10.7%), diarrhea (10.7%), impaired liver function (3.6%), and hand-foot syndrome (1.8%).
  
  
  CONCLUSIONS
  Our study shows that DCS regimen is active against advanced gastric cancer with acceptable toxicities and it may be used as a new choice of first-line chemotherapy for patients with advanced gastric cancer.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
authors.forename: Haiqing
authors.initials: H
authors.lastname: Luo
authors.forename: Zhonghua
authors.initials: Z
authors.lastname: Yu
authors.forename: Hongfei
authors.initials: H
authors.lastname: Gao
authors.forename: Chengnong
authors.initials: C
authors.lastname: Guan
authors.forename: Meng
authors.initials: M
authors.lastname: Xu
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002681:China; D018572:Disease-Free Survival; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D016190:Carboplatin